Development of New Vaccines against Dengue Fever and Japanese Encephalitis

Abstract

Mosquito-borne dengue (DEN) and Japanese encephalitis (JE) viruses are the leading causes of arthropod-transmitted viral disease in humans. A licensed tetravalent vaccine that provides effective, long-term immunity against all four serotypes of DEN virus is needed, but is currently unavailable. Improvements to currently available JE vaccines are also needed. Past and recent strategies for the development of new DEN and JE vaccines include inactivated and live attenuated viruses, engineered viruses and chimeric viruses derived from infectious cDNA clones of DEN or JE virus, recombinant poxviruses, recombinant baculoviruses, protein expression in Escherichia coli, and naked DNA vaccines. This report summarizes some of the recent developments in DEN and JE vaccinology, particularly vaccine strategies that involve live attenuated viruses, engineered viruses derived from infectious cDNA clones, and naked DNA vaccines.

Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico

“…7 Given the lack of effective tools for the primary prevention of dengue, there has been a major effort to develop safe and effective dengue vaccines as a tool to prevent this disease. [10][11][12][13][14] Several dengue vaccines are now in late stage development and will begin to move into large scale clinical trials. [15][16][17] Because dengue is endemic in Puerto Rico, it has been considered as a potential site for a dengue vaccine efficacy trial.…”

Struktur Proteomik Virus Dengue Dan Manfaatnya Sebagai Target Antivirus

“…1 Manifestasi klinis akibat infeksi DENV dapat berupa gejala demam ringan, yang disertai dengan nyeri otot (mialgia), nyeri sendi (arthralgia), bintik kemerahan pada kulit (rash), penurunan jumlah sel leukosit, dan pembengkakan limpa. 2 Demam berdarah dengue merupakan bentuk keparahan dari infeksi DENV yang ditandai dengan hilangnya plasma yang memicu gejala syok. DENV, yang terdiri atas 4 serotipe (DENV-1, DENV-2, DENV-3 & DENV-4), mampu menimbulkan penyakit, mulai dari asimptomatik hingga DBD.…”

“…1 Infeksi DENV telah menginfeksi lebih dari 100 juta jiwa dengan korban jiwa hingga 24.000 setiap tahunnya di dunia, 3 dan lebih dari 50 juta orang yang terinfeksi DENV berasal dari Asia Tenggara, Pasifik Barat, Tengah dan Amerika Selatan. 4 Namun demikian hingga saat ini, belum terdapat vaksin maupun antivirus yang efektif dalam mencegah dan mengobati infeksi DENV. 5 Selama penelitian pengembangan vaksin dan antivirus, telah diperoleh berbagai informasi yang meningkatkan pemahaman tentang siklus hidup DENV, interaksi virus dengan sel inang, dan informasi tentang faktor-faktor penting transmisi virus.…”

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

“…Such data have been generated for the DEN-2 PDK-53 virus ( [29]; summarized in [43]). The NS1-53 attenuation locus (highly stable during passage of the ChiDEN-V viruses in Vero cells), when engineered alone in the genetic background of wildtype DEN-2 16681 virus, encoded nearly complete attenuation of neurovirulence for newborn ICR mice, and decreased plaque size in LLC-MK 2 cells and decreased replicative ability in C6/36 cells to an extent equivalent to that of the single 5′NC-57 attenuating mutation engineered in the 16681 background.…”